TriFoil Imaging has inked a definitive agreement to acquire fellow preclinical imaging technology developer Bioscan.
TriFoil and Bioscan said they intend to combine their in vivo molecular imaging capabilities and technical expertise and provide their technology to universities, pharmaceutical companies, and contract research organizations.
The addition of Bioscan enhances TriFoil's product line with service capabilities and also brings additional imaging technologies, such as 3D optical tomography, TriFoil CEO Kevin Parnham said in a statement.
Bioscan CEO Staf Van Cauter will join TriFoil's management team as vice president of sales, marketing, and business development. Other critical Bioscan employees will also continue on with TriFoil, according to the firm.
